Open Access

Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only

  • Authors:
    • Linda Hertlein
    • Johanna Rath
    • Christine Zeder‑Göss
    • Sophie Fürst
    • Daniela Bayer
    • Fabian Trillsch
    • Sven Mahner
    • Alexander Burges
    • Udo Jeschke
  • View Affiliations

  • Published online on: July 18, 2017     https://doi.org/10.3892/ol.2017.6592
  • Pages: 3302-3308
  • Copyright: © Hertlein et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to identify differences in protein expression in cases of endometrioid endometrial cancer (EEC) with and without coexisting adenomyosis uteri (AM), and to evaluate the histopathological and prognostic distinctions. The total cohort included 22 patients in Group A (patients with concomitant AM and EEC) and 35 patients in Group B (patients affected only by EEC). Evaluation of the following factors was performed: Tumour grade, International Federation of Gynaecology and Obstetrics (FIGO) stage, survival, and expression of estrogen receptor β (ERβ), glycodelin and inhibin βB. Group A (AM and EEC) was associated with a lower tumour grade (G1, 90.9 vs. 45.7%; P=0.001) and a lower FIGO stage (FIGO stage I, 100 vs. 80%; P=0.002) compared with Group B (EEC only). In the survival analysis, Group A was associated with a significantly higher 5‑year survival rate (95 vs. 82%; P=0.024) than Group B. In addition, the expression of ERβ in Group A was significantly higher (P<0.001), whereas the expression of glycodelin is significantly lower (P=0.028), compared with Group B. The results of the present study indicate that the presence of AM in cases of EEC may be a positive prognostic factor.
View Figures
View References

Related Articles

Journal Cover

September-2017
Volume 14 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hertlein L, Rath J, Zeder‑Göss C, Fürst S, Bayer D, Trillsch F, Mahner S, Burges A and Jeschke U: Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncol Lett 14: 3302-3308, 2017.
APA
Hertlein, L., Rath, J., Zeder‑Göss, C., Fürst, S., Bayer, D., Trillsch, F. ... Jeschke, U. (2017). Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncology Letters, 14, 3302-3308. https://doi.org/10.3892/ol.2017.6592
MLA
Hertlein, L., Rath, J., Zeder‑Göss, C., Fürst, S., Bayer, D., Trillsch, F., Mahner, S., Burges, A., Jeschke, U."Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only". Oncology Letters 14.3 (2017): 3302-3308.
Chicago
Hertlein, L., Rath, J., Zeder‑Göss, C., Fürst, S., Bayer, D., Trillsch, F., Mahner, S., Burges, A., Jeschke, U."Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only". Oncology Letters 14, no. 3 (2017): 3302-3308. https://doi.org/10.3892/ol.2017.6592